Home Healthcare Biotechnology Plasma Therapy Market

Plasma Therapy Market Size, Share & Trends Analysis Report By Type (Pure Platelet-rich Plasma, Leukocyte-rich PRP, Pure Platelet-rich Fibrin, Leukocyte-rich Fibrin, Plasma Proteins), By Source (Autologous, Allogenic), By Application (Orthopedic, Chronic Infectious Diseases, Dermatology, Dental, Cardiac Muscle Injury, Nerve Injury), By End User (Hospitals & Clinics, Research Institutions) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 06, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Plasma Therapy Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Pure Platelet-rich Plasma
    2. Leukocyte-rich PRP
    3. Pure Platelet-rich Fibrin
    4. Leukocyte-rich Fibrin
    5. Plasma Proteins
  2. Plasma Therapy Market, By Source 2022-2034 (USD MILLION/ Units)
    1. Autologous
    2. Allogenic
  3. Plasma Therapy Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Orthopedic
    2. Chronic Infectious Diseases
    3. Dermatology
    4. Dental
    5. Cardiac Muscle Injury
    6. Nerve Injury
  4. Plasma Therapy Market, By End User 2022-2034 (USD MILLION/ Units)
    1. Hospitals & Clinics
    2. Research Institutions
  5. Regional Plasma Therapy Market
    1. North America
      1. North America Plasma Therapy Market By Type 2022-2034 (USD MILLION/ Units)
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
      2. North America Plasma Therapy Market By Source 2022-2034 (USD MILLION/ Units)
        1. Autologous
        2. Allogenic
      3. North America Plasma Therapy Market By Application 2022-2034 (USD MILLION/ Units)
        1. Orthopedic
        2. Chronic Infectious Diseases
        3. Dermatology
        4. Dental
        5. Cardiac Muscle Injury
        6. Nerve Injury
      4. North America Plasma Therapy Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research Institutions
      5. U.S.
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      6. Canada
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
    2. Europe
      1. Europe Plasma Therapy Market By Type 2022-2034 (USD MILLION/ Units)
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
      2. Europe Plasma Therapy Market By Source 2022-2034 (USD MILLION/ Units)
        1. Autologous
        2. Allogenic
      3. Europe Plasma Therapy Market By Application 2022-2034 (USD MILLION/ Units)
        1. Orthopedic
        2. Chronic Infectious Diseases
        3. Dermatology
        4. Dental
        5. Cardiac Muscle Injury
        6. Nerve Injury
      4. Europe Plasma Therapy Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research Institutions
      5. U.K.
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      6. Germany
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      7. France
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      8. Spain
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      9. Italy
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      10. Russia
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      11. Nordic
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      12. Benelux
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      13. Rest of Europe
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
    3. APAC
      1. APAC Plasma Therapy Market By Type 2022-2034 (USD MILLION/ Units)
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
      2. APAC Plasma Therapy Market By Source 2022-2034 (USD MILLION/ Units)
        1. Autologous
        2. Allogenic
      3. APAC Plasma Therapy Market By Application 2022-2034 (USD MILLION/ Units)
        1. Orthopedic
        2. Chronic Infectious Diseases
        3. Dermatology
        4. Dental
        5. Cardiac Muscle Injury
        6. Nerve Injury
      4. APAC Plasma Therapy Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research Institutions
      5. China
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      6. Korea
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      7. Japan
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      8. India
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      9. Australia
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      10. Taiwan
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      11. South East Asia
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      12. Rest of Asia-Pacific
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
    4. Middle East and Africa
      1. Middle East and Africa Plasma Therapy Market By Type 2022-2034 (USD MILLION/ Units)
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
      2. Middle East and Africa Plasma Therapy Market By Source 2022-2034 (USD MILLION/ Units)
        1. Autologous
        2. Allogenic
      3. Middle East and Africa Plasma Therapy Market By Application 2022-2034 (USD MILLION/ Units)
        1. Orthopedic
        2. Chronic Infectious Diseases
        3. Dermatology
        4. Dental
        5. Cardiac Muscle Injury
        6. Nerve Injury
      4. Middle East and Africa Plasma Therapy Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research Institutions
      5. UAE
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      6. Turkey
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      7. Saudi Arabia
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      8. South Africa
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      9. Egypt
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      10. Nigeria
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      11. Rest of MEA
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
    5. LATAM
      1. LATAM Plasma Therapy Market By Type 2022-2034 (USD MILLION/ Units)
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
      2. LATAM Plasma Therapy Market By Source 2022-2034 (USD MILLION/ Units)
        1. Autologous
        2. Allogenic
      3. LATAM Plasma Therapy Market By Application 2022-2034 (USD MILLION/ Units)
        1. Orthopedic
        2. Chronic Infectious Diseases
        3. Dermatology
        4. Dental
        5. Cardiac Muscle Injury
        6. Nerve Injury
      4. LATAM Plasma Therapy Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research Institutions
      5. Brazil
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      6. Mexico
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      7. Argentina
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      8. Chile
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      9. Colombia
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
      10. Rest of LATAM
        1. Pure Platelet-rich Plasma
        2. Leukocyte-rich PRP
        3. Pure Platelet-rich Fibrin
        4. Leukocyte-rich Fibrin
        5. Plasma Proteins
        6. Autologous
        7. Allogenic
        8. Orthopedic
        9. Chronic Infectious Diseases
        10. Dermatology
        11. Dental
        12. Cardiac Muscle Injury
        13. Nerve Injury
        14. Hospitals & Clinics
        15. Research Institutions
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.